Estudio multicéntrico comparativo sobre tolerancia y eficacia de terfenadina vs. placebo en urticaria crónica / Comparative multicenter study on the tolerance and efficacy of terfenadine vs. placebo in chronic urticaria

La terfenadina es un nuevo bloqueador específico de los receptores H1 periféricos. Diversos estudios clínicos realizados en los Estados Unidos y Europa han demostrado su eficacia en el tratamiento de la urticaria y la rinitis alérgica, así como la ausencia de efecto sedante, incluso cuando se administra conjuntamente con tranquilizantes o alcohol. El objetivo de nuestro estudio fue una evaluación comparativa de la tolerancia y eficacia de terfenadina y placebo, en el tratamiento de urticaria crónica, en pacientes latinoamericanos

[The Buckley syndrome: recurring, severe staphylococcal infections, eczema and hyperimmunoglobulinemia E. (author's transl)]. / Das Buckley-Syndrom: Rezidivierende, schwere Staphylokokken-infektionen, Ekzem und Hyperimmunglobulinmie E.

Fifteen patients aged between three and 27 years were examined clinically and immunologically. Common to all patients were severe recurring cutaneous and pulmonary staphyloccal infections, chronic eczema, eosinophilia and an extremely elevated serum IgE level. Eight of the patients had in addition facial dysplasia characterised by coarse features, prognathism and poorly formed external ears. Marked osteoporosis, particularly of the vertebral bodies, was observed in eight patients. A constant defect of granulocyte chemotaxis was found in only three patients; fluctuating or constantly normal chemotaxis occurred in six patients. Polycloncal hypergammaglobulinemia was detected in 14 patients, elevated IgD in two patients, a partial T-cell defect in two patients and a history of lack of antibody response in one patient. Therapeutic trails anti-H2 receptor-antihistamines did not produce lasting or satisfactory clinical or immunological results in the pathogenetically unidentified disease.